President Trump signed into law Oct. 24 the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act that gives the US FDA new authorities to tackle the opioid crisis, exemplifying a potential conundrum of whether the agency is over-promising or overreacting on the epidemic.
Richard Cooper, who served as FDA chief counsel from 1977 to 1979, questioned whether FDA Commissioner Scott Gottlieb has set...







